⌘K

Login Start Free

Home/Filings/4/0001213900-23-097029

4//SEC Filing

Kelly Paul Edward 4

Accession 0001213900-23-097029

CIK 0001553643other

View on SEC.gov Company Profile

Filed

Dec 18, 7:00 PM ET

Accepted

Dec 19, 5:28 PM ET

Size

5.4 KB

Accession

0001213900-23-097029

Insider Transaction Report

Form 4

Period: 2023-12-15

RELMADA THERAPEUTICS, INC.RLMD

Kelly Paul Edward

DirectorChief Operating Officer

Transactions

Award
Stock Option (right to buy)
2023-12-15+65,672→ 65,672 total
Exercise: $2.48From: 2024-03-15Exp: 2033-12-15→ Common Stock (65,672 underlying)

Footnotes (1)

[F1]The option vests in 16 equal quarterly installments commencing on March 15, 2024.

Documents

1 file

4
ownership.xmlPrimary

Issuer

RELMADA THERAPEUTICS, INC.

CIK 0001553643

Entity typeother

Related Parties

1

filerCIK 0001658544

Filing Metadata

Form type: 4
Filed: Dec 18, 7:00 PM ET
Accepted: Dec 19, 5:28 PM ET
Size: 5.4 KB

View on SEC.gov